CTLA4 and neoplasm: For example, ipilimumab is the first immune checkpoint blocker approved by the Food and Drug Administration and has been thought to work through inhibiting CTLA-4 on effector T cells as well as on Treg cells by depleting Treg cells in the tumor microenvironment3,4.